InflaRx Faces Nasdaq Listing Challenge Over Stock Price Compliance Issue

PessimisticOracle · 2025-12-31T10:33:12+00:00

InflaRx N.V. received a compliance notice from Nasdaq for failing to meet the $1.00 minimum bid price for 30 days. It has 180 days to restore compliance or may transfer to Nasdaq Capital Market for an additional extension. The company continues to monitor its stock status while advancing its anti-inflammatory treatments.

PessimisticOracle

2025-12-31 10:33:12

Abstract generation in progress

InflaRx N.V. (Nasdaq: IFRX), the Germany-based biopharmaceutical firm specializing in anti-inflammatory therapeutics targeting the complement system, has disclosed a significant compliance notice from Nasdaq’s Listing Qualifications Department on July 11, 2025.

The Core Issue: Stock Price Below Minimum Threshold

The company’s common shares have closed below the mandatory $1.00 minimum bid price for 30 consecutive business days, breaching Nasdaq’s Listing Rule 5450(a)(1). This technical deficiency places InflaRx in a precarious position regarding its continued presence on The Nasdaq Global Select Market.

Timeline and Compliance Pathways

Under Nasdaq Listing Rule 5810©(3)(A), InflaRx has been granted an initial 180-calendar-day compliance window extending until January 7, 2026, to restore its stock price above the required threshold.

Should the company fail to meet this deadline, a secondary option exists: transferring to The Nasdaq Capital Market. This alternative route would provide an additional 180-calendar-day period, extending the total compliance window to July 6, 2026—contingent upon meeting all other applicable market value and listing requirements.

However, no guarantee exists that Nasdaq would approve either pathway. The transfer eligibility and final listing determination remain at Nasdaq’s discretion.

Current Status and Operational Impact

The notice does not immediately affect trading activity or listing status of InflaRx shares. The company maintains its position on Nasdaq while actively monitoring bid prices and evaluating strategic options to regain compliance.

InflaRx’s Therapeutic Pipeline and Technology Platform

InflaRx specializes in developing targeted anti-inflammatory treatments by inhibiting C5a and its receptor—a powerful complement activation factor implicated in numerous inflammatory diseases. The company’s lead candidate, vilobelimab, represents a first-in-class intravenously administered anti-C5a monoclonal antibody that has demonstrated disease-modifying efficacy across multiple clinical trials.

Additionally, InflaRx is advancing INF904, an oral small molecule inhibitor targeting C5a-induced signaling pathways, expanding treatment accessibility beyond IV administration.

Company Background

Founded in 2007, InflaRx operates through subsidiaries across Jena and Munich in Germany and Ann Arbor, Michigan in the United States. The organization’s focused research on complement system modulation positions it within a specialized segment of the biopharmaceutical industry.

The path forward for InflaRx depends on executing strategic initiatives to restore investor confidence and achieve compliance with Nasdaq’s pricing requirements within the designated timeframe.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.